Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Adults and Children
NCT03109600Phase 1Completed
- Sponsor
- Bio Farma
- Start
- Apr 2017
- Primary completion
- Sep 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of typhoid conjugate vaccine in typhoid fever (4 arms), sponsored by Bio Farma. Primary endpoint: Local reaction and systemic event after vaccination at 28 days. Started Apr 2017; status: completed.
02
Drugs
typhoid conjugate vaccine
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT03109600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109600.